Galapagos NV

Inactive

GLPG (NasdaqGS)

Galapagos NV is a biotechnology company focused on developing medicines for oncology and immunology in the United States and Europe. Its product pipeline includes GLPG3667 (completed phase 1b), GLPG5101 (CD19 CAR-T, point-of-care, in phase 1/2 for relapsed/refractory non-Hodgkin lymphoma), GLPG5201 (CD19 CAR-T, point-of-care, in phase 1/2 for relapsed/refractory CLL), and GLPG5301 (BCMA CAR-T, point-of-care, in phase 1/2 for relapsed/refractory multiple myeloma). It collaborates with Gilead Sciences and AbbVie. Incorporated in 1999 and headquartered in Mechelen, Belgium.